Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | SCD | O00767 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470957 | 0.90 | HPGD (0.62) | HPGDTSHRHTTALDH1A1SCD | |
| SCHEMBL31428937 | 0.90 | HPGD (0.60) | HPGDTSHRHTTALDH1A1KDM4E | |
| SCHEMBL14970147 | 0.88 | HPGD (0.81) | HPGDTSHRHTTALDH1A1SCD | |
| SCHEMBL12963767 | 0.87 | HPGD (0.79) | HPGDTSHRHTTALDH1A1SCD | |
| SCHEMBL3089549 | 0.85 | HPGD (0.65) | HPGDTSHRHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL3089547 | 0.82 | HPGD (0.63) | HPGDTSHRHTTALDH1A1SCD | |
| SCHEMBL31428953 | 0.82 | HPGD (0.63) | HPGDTSHRHTTALDH1A1SCD | |
| SCHEMBL16002927 | 0.81 | HPGD (0.69) | HPGDTSHRHTTALDH1A1KDM4E | |
| SCHEMBL31428750 | 0.80 | HPGD (0.65) | HPGDTSHRHTTALDH1A1KDM4E | |
| SCHEMBL22242682 | 0.80 | HPGD (0.67) | HPGDTSHRALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116535-B1 | GLUCOKINASE-ACTIVATING SUBSTANCE | KYORIN SEIYAKU KK (JP) | 2014-06-11 | — | — | EP | disclosed |
| US-8173649-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173649-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100016304-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016304-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016304-A1 | GLUCOKINASE ACTIVATOR | GCK, GCKR, GALK1 | HPGD 2858/4885TSHR 1676/4885HTT 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.